Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

773P - Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Ovarian Cancer

Presenters

Hui Li

Citation

Annals of Oncology (2021) 32 (suppl_5): S725-S772. 10.1016/annonc/annonc703

Authors

H. Li, M. Wu, Z. Wu, J. Liang, L. Wang, J. Li, Z. Lin

Author affiliations

  • Department Of Gynecological Oncology, 2nd Affiliated Hospital of Sun Yat-sen University, 510308 - Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 773P

Background

Epithelial ovarian cancer (EOC) is commonly regarded as the deadliest gynecological cancer, and the demand for novel noninvasive prognostic biomarkers remains significant. This study aimed to investigate the prognostic value of preoperative blood biomarkers in EOC patients and the correlation of IL2RA mRNA expression with the tumor immune microenvironment (TIME).

Methods

A total of 73 patients who had undergone surgery for an ovarian mass were included in this study. Serum concentrations of blood biomarkers, including soluble interleukin 2 receptor α (sIL-2R), were measured 1-2 weeks before surgery. Independent prognostic factors for progression-free survival (PFS) were investigated with multivariate Cox regression analysis. A prognostic model was subsequently developed and evaluated in terms of discrimination, calibration and clinical net benefit. Furthermore, transcriptome data of 376 EOC cases from The Cancer Genome Atlas (TCGA) analyzed with ESTIMATE and CIBERSORT computational methods to evaluate the correlation of IL2RA mRNA expression with TIME.

Results

The sIL-2R concentration was positively correlated with advanced stage and negatively correlated with PFS. A high sIL-2R concentration was found to be the only significant prognostic blood biomarker for PFS by multivariate Cox regression analysis. A prognostic nomogram was developed with satisfactory discrimination, calibration and clinical net benefit. ESTIMATE analysis of TCGA transcriptome data demonstrated that higher IL2RA expression was significantly associated with higher immune scores. And CIBERSORT analysis of the tumor-infiltrating lymphocytes (TILs) profile demonstrated that IL2RA expression was positively correlated with activated CD4+ T cells, M2 macrophages and resting dendritic cells in EOC.

Conclusions

sIL-2R is a potential prognostic immune biomarker for EOC patients, and a comprehensive prognostic model comprising sIL-2R with satisfactory discrimination and clinical appliance was developed. sIL-2R may also play a vital role in the EOC immune response by regulating immune cell infiltration. Therefore, we recommend routinely measuring sIL-2R in EOC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.